Comparison tool
Tirzepatide vs Setmelanotide side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Tirzepatide | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Also known as | Mounjaro, Zepbound, LY3298176 | Imcivree, RM-493 |
| FDA approved | Yes | Yes |
| Clinical status | FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea
| FDA approved for specified rare obesity indications including BBS, POMC/PCSK1/LEPR deficiency, and acquired hypothalamic obesity.
|
| What to expect | Weight loss, diabetes management, metabolic health | Genetic obesity disorders and rare metabolic conditions |
| How it works | Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved. | Setmelanotide is reported as a melanocortin-4 receptor agonist. The supplied mechanism evidence places MC4R downstream of leptin and POMC signaling in hypothalamic appetite regulation. For rare conditions such as POMC, PCSK1, or LEPR deficiency, the source states that upstream signaling can be impaired while MC4R remains a target; direct MC4R agonism is therefore presented as the rationale for its narrow genetic-obesity use. |
| Typical dosing | 5-15 mg weekly (after titration) · Once weekly | 2-3 mg daily · Once daily · Subcutaneous injection |
| Research dosing | 2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly | 2-3 mg daily in adults · Long-term / chronic use · Subcutaneous injection daily |
| Typical duration | Long-term / chronic use | Long-term / chronic use |
| Administration | Subcutaneous injection weekly | Subcutaneous injection |
| Timing | Morning, same day each week With or without food | Beginning of the day Without regard to meals |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+9 more
|
+4 more
|
| Research summary | The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results. | The supplied source summarizes clinical evidence as narrow but strong for rare disease populations. It reports pivotal open-label, single-arm phase 3 studies in POMC and LEPR deficiency, with at least 10% weight loss at about one year in 80% of POMC participants and 45% of LEPR participants, plus reduced hunger scores. The source also cites a randomized placebo-controlled phase 3 study for Bardet-Biedl syndrome and a 2024 VENTURE open-label study including children as young as two. Because the conditions are rare, the evidence base is described as small and indication-specific rather than broadly applicable to common obesity. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.